Galmed Pharmaceuticals
GLMD
20 hedge funds and large institutions have $17.7M invested in Galmed Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding
Funds holding: 20 → 20 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
8% less capital invested
Capital invested by funds: $19.3M → $17.7M (-$1.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$1.78M |
| 2 |
6CM
683 Capital Management
New York
|
+$903K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$221K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$137K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$33.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.46M |
| 2 |
HM
HealthCor Management
New York
|
-$814K |
| 3 |
SCM
Sterling Capital Management
Charlotte,
North Carolina
|
-$125K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$92.1K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$23K |
GLMD Hedge Fund Activity: Q2 2014 in Review
20 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2014, worth a combined $17.7M — down 8% from $19.3M a quarter earlier.
Fund positioning in GLMD was balanced in Q2 2014: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Pine River Capital Management, opening a new position worth an estimated $1.78M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $1.46M sold.
- 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $17.7M of Galmed Pharmaceuticals stock for Q2 2014, down 8% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q2 2014 and 4 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2014 was Pine River Capital Management, an estimated $1.78M added.
- The largest Galmed Pharmaceuticals seller in Q2 2014 was Highland Capital Management (Texas), an estimated $1.46M sold.
Based on aggregated 13F filings for Q2 2014.